Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Medicinas Complementares
Métodos Terapêuticos e Terapias MTCI
Tipo de documento
Intervalo de ano de publicação
1.
Korean Circulation Journal ; : 960-969, 2017.
Artigo em Inglês | WPRIM | ID: wpr-123311

RESUMO

BACKGROUND AND OBJECTIVES: Dilated cardiomyopathy can be the end-stage of severe cardiac disorders and directly affects the cardiac muscle, inducing cardiomegaly and heart failure (HF). Although a wide variety of animal models are available to study dilated cardiomyopathy, there is no model to assess dilated cardiomyopathy with non-invasive, simple, and large screening methods. METHODS: We developed a dilated cardiomyopathy model in zebrafish larvae using short duration terfenadine, a known cardiotoxic drug that induces ventricular size dilation. Fractional shortening of zebrafish hearts was calculated. RESULTS: We treated zebrafish with 5 to 10 µM terfenadine for 24 hours. In terfenadine-treated zebrafish, blood frequently pooled and clotted in the chamber, and circulation was remarkably reduced. Atria and ventricles were swollen, and fluid was deposited around the heart, mimicking edema. Cardiac contractility was significantly reduced, and ventricular area was significantly enlarged. Heart rate was markedly reduced even after terfenadine withdrawal. Acridine orange staining also showed that terfenadine increased cardiomyocyte apoptosis. A significant increase of natriuretic peptide B (NPPB) mRNA was found in terfenadine-treated zebrafish. A low dose of terfenadine (5–10 µM) did not show mortality in short-term treatment (24 hours). However, moderate dose (35–45 µM) terfenadine treatment reduced zebrafish survival within 1 hour. CONCLUSION: With advantages of rapid sample preparation procedure and transparent observation of the live heart, this model can potentially be applied to large-scale drug screening and toxicity assays for non-ischemic HF.


Assuntos
Laranja de Acridina , Apoptose , Cardiomegalia , Cardiomiopatias , Cardiomiopatia Dilatada , Avaliação Pré-Clínica de Medicamentos , Edema , Coração , Insuficiência Cardíaca , Frequência Cardíaca , Larva , Programas de Rastreamento , Modelos Animais , Mortalidade , Miocárdio , Miócitos Cardíacos , RNA Mensageiro , Terfenadina , Peixe-Zebra
2.
Artigo em Inglês | WPRIM | ID: wpr-221143

RESUMO

The effect of NaCl plus 3% chitosan on the systolic blood pressure of spontaneously hypertensive rats (SHR) were evaluated and compared with NaCl plus KCl (NaCl, 49.36% + KCl 49.36%) and chitosan or NaCl treatment alone. In SHR, administration of NaCl plus chitosan (44 mM Na/day) for two months significantly decreased the systolic blood pressure greater than of NaCl plus KCl and NaCl alone. NaCl plus chitosan resulted, though not statistically significant, in decreased urinary Na+ excretion and decreased blood urea nitrogen levels. Urinary creatinine of NaCl plus chitosan was slightly decreased compared to 3 treated groups. Serum electrolytes levels, however, remained unchanged. The combination of NaCl and chitosan may be superior to the conventional use of NaCl plus KCl or NaCl alone in the prevention of hypertension. Even though these supplementary diets have demonstrated potential anti-hypertensive effects in the experimental animal model, further research is needed before any recommendations can be made.


Assuntos
Animais , Masculino , Ratos , Angiotensina I/sangue , Angiotensina II/biossíntese , Pressão Sanguínea/efeitos dos fármacos , Nitrogênio da Ureia Sanguínea , Peso Corporal/efeitos dos fármacos , Quitosana/administração & dosagem , Cloretos/sangue , Creatinina/urina , Coração/fisiologia , Histocitoquímica , Hipertensão/prevenção & controle , Rim/fisiologia , Potássio/sangue , Cloreto de Potássio/administração & dosagem , Distribuição Aleatória , Ratos Endogâmicos SHR , Sódio/sangue , Cloreto de Sódio na Dieta/administração & dosagem , Sístole/efeitos dos fármacos
3.
Artigo em Inglês | WPRIM | ID: wpr-7147

RESUMO

An herbal extract mixture and yogurt added to the herbal extract mixture were tested for their protective and therapeutic effects on ethanol-induced liver injury. The herbal extract mixture, yogurt and commercial drugs were used for treatment for two weeks prior to administering a single oral dose of ethanol (3 g/kg body weight). The herbal extract mixture and yogurt added to the herbal extract mixture were found to provide protection against ethanolinduced toxicity comparable to the commercial drug treatment, according to the serum and histopathological analysis. It was also shown that co-treatment with herbal extract mixture and yogurt against a triple oral dose of ethanol (2 g/kg body weight, over one week) provided protection against ethanol toxicity. After the initial set of experiments, the herbal extract mixture and yogurt treatments were extended for three more weeks. When compared to the positive control, further treatment with both the herbal extract and yogurt significantly reduced liver injury and resulted in a lower grade of lipid deposition.


Assuntos
Animais , Masculino , Ratos , Alnus/química , Peso Corporal/efeitos dos fármacos , Brassica napus/química , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Ingestão de Alimentos , Etanol/antagonistas & inibidores , Fabaceae/química , Fermentação , Fígado/patologia , Silybum marianum/química , Oryza/química , Fitoterapia , Extratos Vegetais/uso terapêutico , Ratos Sprague-Dawley , Iogurte
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA